Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for Lipoprotein(a)-Lowering therapies: JACC focus seminar 2/3. J Am Coll Cardiol. 2023;81. https://doi.org/10.1016/j.jacc.2023.02.033.

Colantonio LD, Bittner V, Safford MM. Lipoprotein(a) and the risk for coronary heart disease and ischemic stroke events among Black and White adults with cardiovascular disease. J Am Heart Assoc. 2022. https://doi.org/10.1161/JAHA.121.025397.

Article  PubMed  PubMed Central  Google Scholar 

Volgman AS, Koschinsky ML, Mehta A, Rosenson RS. Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk. J Am Heart Assoc. 2024. https://doi.org/10.1161/JAHA.123.033654.

Article  PubMed  PubMed Central  Google Scholar 

Dai N, Chen Z, Zhou F, et al. Association of lipoprotein (a) with coronary-Computed tomography Angiography–Assessed High-Risk coronary disease attributes and cardiovascular outcomes. Circ Cardiovasc Imaging. 2022. https://doi.org/10.1161/CIRCIMAGING.122.014611.

Article  PubMed  Google Scholar 

Nurmohamed NS, Gaillard EL, Malkasian S, et al. Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation. JAMA Cardiol. 2024. https://doi.org/10.1001/jamacardio.2024.1874.

Article  PubMed  PubMed Central  Google Scholar 

Senoner T, Plank F, Beyer C. Gender differences in the atherosclerosis profile by coronary CTA in coronary artery calcium score zero patients. J Clin Med. 2021. https://doi.org/10.3390/jcm10061220.

Article  PubMed  PubMed Central  Google Scholar 

Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF. Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women. J Am Coll Cardiol. 2000. https://doi.org/10.1016/S0735-1097(99)00555-0.

Article  PubMed  Google Scholar 

Martignoni FV, RL Júnior JE, Marques IR. The association of lipoprotein(a) and coronary artery calcium in asymptomatic patients: a systematic review and meta-analysis. Eur J Prev Cardiol. 2024. https://doi.org/10.1093/eurjpc/zwae043.

Article  PubMed  Google Scholar 

O’Donoghue ML, Fazio S, Giugliano RP. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.

Article  PubMed  PubMed Central  Google Scholar 

Bittner V, Szarek M, Aylward P. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2019.10.057.

Article  PubMed  Google Scholar 

Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals. 2023. https://doi.org/10.3390/ph16040577.

Article  PubMed  PubMed Central  Google Scholar 

Kini AS, Vengrenyuk Y, Shameer K, et al. Intracoronary Imaging, cholesterol Efflux, and transcriptomes after intensive Statin treatment: the YELLOW II study. J Am Coll Cardiol. 2017;69. https://doi.org/10.1016/j.jacc.2016.10.029.

Mintz GS, Nissen SE, Anderson WD, et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus): A report of the American college of cardiology task force on clinical expert consensus documents developed in collaboration with the European society of cardiology endorsed by the society of cardiac angiography and interventions. J Am Coll Cardiol. 2001;37. https://doi.org/10.1016/S0735-1097(01)01175-5.

Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for Acquisition, Measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol. 2012;59. https://doi.org/10.1016/j.jacc.2011.09.079.

Kini AS, Vengrenyuk Y, Yoshimura T, et al. Fibrous cap thickness by optical coherence tomography in vivo. J Am Coll Cardiol. 2017;69. https://doi.org/10.1016/j.jacc.2016.10.028.

Araki M, Mario CD, Guagliumi G, et al. Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat Rev Cardiol. 2022;19. https://doi.org/10.1038/s41569-022-00687-9.

Kaiser Y, Daghem M, Tzolos E, et al. Association of Lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79. https://doi.org/10.1016/j.jacc.2021.10.044.

Mszar R, Cainzos-Achirica M, Valero-Elizondo J, et al. Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami heart study at baptist health South Florida. Circ Cardiovasc Imaging. 2024;17. https://doi.org/10.1161/CIRCIMAGING.123.016152.

Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74. https://doi.org/10.1161/01.CIR.74.4.758.

Puri R, Ballantyne CM, Hoogeveen RC, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity Statin therapy: insights from SATURN. Atherosclerosis. 2017;263. https://doi.org/10.1016/j.atherosclerosis.2017.06.026.

Hartmann M, Birgelen Cv, Mintz GS, et al. Relation between Lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006;48. https://doi.org/10.1016/j.jacc.2006.03.047.

Huded CP, Shah NP, Puri R, et al. Association of serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound. J Am Heart Association. 2020;9. https://doi.org/10.1161/JAHA.120.018023.

Niccoli G, Cin D, Scalone G, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246. https://doi.org/10.1016/j.atherosclerosis.2016.01.020.

Muramatsu Y, Minami Y, Kato A, et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: an optical coherence tomography study. IJC Heart Vasculature. 2019;24. https://doi.org/10.1016/j.ijcha.2019.100382.

Muro FMD, Crociani MF, Nardi G, et al. Coronary plaque characteristics assessed by optical coherence tomography and plasma lipoprotein(a) levels in patients with acute coronary syndrome. Catheter Cardiovasc Interv. 2024. https://doi.org/10.1002/ccd.31363.

Article  PubMed  PubMed Central  Google Scholar 

Yonetsu T, Kakuta T, Lee T, et al. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J. 2011;32. https://doi.org/10.1093/eurheartj/ehq518.

Koskinas KC, Häner J, Ueki Y, et al. Association of Lipoprotein(a) with changes in coronary atherosclerosis in patients treated with Alirocumab. Circ Cardiovasc Imaging. 2024;17. https://doi.org/10.1161/CIRCIMAGING.124.017613.

Burgess S, Ference BA, Staley JR, et al. LPA Variants, risk of coronary Disease, and estimated clinical benefit of Lipoprotein(a)-Lowering therapies. JAMA Cardiol. 2018;3. https://doi.org/10.1001/jamacardio.2018.1470.

Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention. Arterioscler Thromb Vasc Biol. 2020;40. https://doi.org/10.1161/ATVBAHA.119.312951.

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41. https://doi.org/10.1093/eurheartj/ehz310.

Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016. https://doi.org/10.1194/jlr.R061648.

Article  PubMed  Google Scholar 

Heydari M, Rezayi M, Ruscica M, Jpamialahamdi T, Johnston TP, Sahebkar A. The Ins and outs of lipoprotein(a) assay methods. Archives Med Sci Atherosclerotic Dis. 2023;8. https://doi.org/10.5114/amsad/176653.